Scynexis (SCYX) EBT Margin (2013 - 2026)
Scynexis' (SCYX) quarterly EBT Margin came in at 3017.02% in Q2 2026, down 251226.0% on a YoY basis from N/an in Q2 2025, and down 4689.28% quarter-over-quarter from 65.74% in Q4 2025.
Powered by 
Analysis
Scynexis (SCYX) EBT Margin (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported EBT Margin for 13 consecutive years, with 3017.02% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 251226.0% year-over-year to 3017.02%; the trailing twelve-month figure through Jun 2026 stood at 103.19% (up 50728.0% YoY), and the FY2025 full-year result was 41.79%, up 52247.0% from the prior year.
- EBT Margin slipped to 3017.02% in Q2 2026 per SCYX's latest filing, from 65.74% in the prior quarter.
- Across five years, EBT Margin topped out at 93.01% in Q2 2023 and bottomed at 3017.02% in Q2 2026.
- Historically, EBT Margin has averaged 1153.16% across 5 years, with a median of 946.78% in 2022.
- The sharpest annual moves came in 2022 and 2026: EBT Margin soared 395925 bps in 2022, then tumbled 251226 bps in 2026.
- Over 5 years, EBT Margin stood at 946.78% in 2022, then jumped by 65 bps to 335.12% in 2023, then sank by 35 bps to 451.38% in 2024, then surged by 115 bps to 65.74% in 2025, then plunged by 4689 bps to 3017.02% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 3017.02%, 65.74%, and 2572.16% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -20,427.46% |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -3,017.02% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,017.02% |
| Dec 31, 2025 | 65.74% |
| Sep 30, 2025 | -2,572.16% |
| Jun 30, 2025 | -504.77% |
| Mar 31, 2025 | -2,097.67% |
| Dec 31, 2024 | -451.38% |
| Sep 30, 2024 | -485.30% |
| Jun 30, 2024 | -1,964.40% |
| Mar 31, 2024 | 68.61% |
| Dec 31, 2023 | -335.12% |
| Sep 30, 2023 | -99.77% |
| Jun 30, 2023 | 93.01% |
| Mar 31, 2023 | -2,997.88% |
| Dec 31, 2022 | -946.78% |
| Sep 30, 2022 | -1,900.06% |
| Jun 30, 2022 | -1,008.69% |
| Mar 31, 2022 | -1,450.14% |
| Dec 31, 2021 | -4,906.03% |
| Sep 30, 2021 | -126.94% |
| Mar 31, 2021 | -29.68% |